It is well established that mCD86 is expressed by AML myeloblasts in a considerable proportion of patients with acute myeloid leukemia in which substantial number of patients have expressed CD86 molecules.59,60 In our pathway analysis, CD86 stayed on downstream of inhibited regulators; so, it is expected that CD86 downregulated in APL patients. The gene discussed is CD86; the disease is acute myeloid leukemia.